Clinical trials: Advanced Disease
Acute Myelogenous Leukemia, Chronic Myelogenous Leukemia
A Phase 1/2 Study of SB1518 for the Treatment of Advanced Myeloid Malignancies
This study consists of two phases: the first portion of the study is a Phase 1 dose escalation study to determine the maximum tolerated dose and the dose limiting toxicities of SB1518 when given as a single agent orally once…
- Conditions
- Acute Myelogenous Leukemia, Chronic Myelogenous Leukemia, Chronic Myelomonocytic Leukemia, Myelodysplastic Syndromes
- Trial name
- NCT00719836
- Testing
- SB1518
- Where
- 3 sites in United States
- Volunteers
- 76 people
- Sponsor
- S*BIO
Breast Cancer
Improved Breast Cancer Therapy (I-BCT-1) in the Neoadjuvant and Metastatic Setting
The purpose of the study is to investigate the molecular biology of the tumor in relation to treatment response to chemotherapy, in particular paclitaxel compared to the combination paclitaxel and carboplatin.
- Trial name
- NCT02546232
- Testing
- Carboplatin, Paclitaxel
- Where
- Norway
- Volunteers
- 196 people
- Sponsor
- Oslo University Hospital
Ovarian Carcinoma, Fallopian Tube Carcinoma
NM32-2668 in Adult Patients With Selected Advanced Solid Tumors
This is a first-in-human, open-label, multi-center, Phase 1, dose-escalation study with expansion cohorts to evaluate NM32-2668 for safety and immunogenicity, to determine the maximal tolerated dose and recommended Phase 2 dose…
- Conditions
- Ovarian Carcinoma, Fallopian Tube Carcinoma, Peritoneal Carcinoma, Endometrial Cancer
- Trial name
- NCT06299163
- Testing
- NM32-2668
- Where
- 11 sites in United States
- Volunteers
- 11 people
- Sponsor
- Numab Therapeutics AG
Triple Negative Breast Cancer, Residual Disease
A Phase I Study of Niraparib Administered Concurrently With Postoperative RT in Triple Negative Breast Cancer Patients
This research study involves Niraparib as a possible treatment for triple negative breast cancer.
- Trial name
- UNITY (NCT03945721)
- Testing
- Niraparib, Radiation Therapy
- Where
- 2 sites in United States
- Volunteers
- 21 people
- Sponsor
- Massachusetts General Hospital
RAS Mutation, NRAS Gene Mutation
NAUTILUS: OKI-179 Plus Binimetinib in Patients with Advanced Solid Tumors in the RAS Pathway (Phase 1b) and NRAS-mutated Melanoma (Phase 2)
The NAUTILUS study is a Phase 1b/2, multi-center, open-label study in which patients with activating mutations in the RAS pathway (Phase 1b) and patients with NRAS-mutated Melanoma (Phase 2) will be treated with a combination of…
- Conditions
- RAS Mutation, NRAS Gene Mutation, Melanoma
- Trial name
- NCT05340621
- Testing
- OKI-179 + binimetinib
- Where
- 12 sites in United States
- Volunteers
- 36 people
- Sponsor
- OnKure, Inc.
Rectal Cancer, Neoadjuvant Therapies
Modified Long-Course Radiotherapy Followed by Chemotherapy and PD-1 Inhibitor for MSS/pMMR High-risk Mid/Low LARC (MODIFI-RC-I)
The goal of this clinical trial is to evaluate whether a total neoadjuvant therapy (TNT) regimen combining long-course chemoradiotherapy, sequential chemotherapy, and PD-1 inhibitor can improve response rates, enhance…
- Conditions
- Rectal Cancer, Neoadjuvant Therapies, Immune Checkpoint Therapy, Radiotherapy
- Trial name
- NCT06923345
- Testing
- Reduced CTV, Conventional CTV
- Where
- China
- Volunteers
- 80 people
- Sponsor
- Sixth Affiliated Hospital, Sun Yat-sen University
Esophageal Squamous Cell Carcinoma (ESCC)
Induction Chemo-Immunotherapy + Radiotherapy vs Concurrent Chemoradiotherapy for Unresectable Locally Advanced Esophageal Squamous Cell Carcinoma
This is a prospective, randomized, phase II clinical study in patients with unresectable stage III-IVA esophageal squamous cell carcinoma (ESCC). Eligible patients will be randomly assigned in a 1:1 ratio to two treatment groups.
- Trial name
- NCT07559045
- Testing
- Paclitaxel plus Cisplatin or Carboplatin (Induction Chemotherapy), Weekly Paclitaxel plus Cisplatin or Carboplatin (Concurrent Chemotherapy)
- Where
- China
- Volunteers
- 92 people
- Sponsor
- Second Affiliated Hospital of Zunyi Medical University
Peripheral Arterial Disease (PAD), Claudication, Intermittent
Expression of GLP1 Receptor on Peripheral Blood Mononuclear Cells in Advanced Peripheral Artery Disease: Paving the Way for GLP1R Agonists Treatment in Chronic Limb Threatening Ischemia
The goal of this observational study is to learn whether activation of the GLP-1 receptor could represent a therapeutic target by characterizing its expression and associated inflammatory mechanisms in patients with peripheral…
- Conditions
- Peripheral Arterial Disease (PAD), Claudication, Intermittent, Chronic Limb-Threatening Ischemia
- Trial name
- EXCEL-CLTI (NCT07340112)
- Testing
- Analysis of GLP-1 receptor expression
- Where
- France
- Volunteers
- 50 people
- Sponsor
- University Hospital, Strasbourg, France
Colorectal Cancer
A Phase 1 Study of OCV-C02 in Patients With Advanced or Relapsed Colorectal Cancer
To assess the safety and tolerability of OCV-C02 in Patients With Advanced or Relapsed Colorectal Cancer Who Are Refractory or Intolerant to Standard Chemotherapy
- Trial name
- NCT01801930
- Testing
- OCV-103 and OCV-104
- Where
- 3 sites in Japan
- Volunteers
- 24 people
- Sponsor
- Otsuka Pharmaceutical Co., Ltd.
Hepatocellular Carcinoma
Prevention of Hand-foot Skin Reaction
Sorafenib-induced hand-foot skin reaction (HFSR) is a dose-dependent side effect in patients with advance hepatocellular carcinoma (HCC).
- Trial name
- NCT04568330
- Testing
- best support care, moisture cream, 10% urea-based cream
- Volunteers
- 129 people
- Sponsor
- Taipei Veterans General Hospital, Taiwan
Diabetes Mellitus, Cellular Senescence
Effect of Sodium-glucose Cotransporter-2 Inhibitor in Cellular Senescence in Patients With Cardiovascular Diseases or Type 2 Diabetes
Patients with type 2 diabetes (T2D) are more prevalent with aging-related comorbidities and frailty, which leads to a shorter life expectancy than non-diabetic individuals and that this excess mortality is largely attributable to…
- Conditions
- Diabetes Mellitus, Cellular Senescence, Sodium-Glucose Transporter 2 Inhibitors
- Trial name
- NCT05975528
- Testing
- SGLT2 inhibitor, Glimepiride
- Where
- South Korea
- Volunteers
- 92 people, healthy volunteers welcome
- Sponsor
- Yonsei University
Cancer, Advanced Cancer
A Study to Evaluate Safety, Tolerability and Preliminary Activity of AGX101 in Participants With Advanced Solid Tumors
AGX101 is an antibody-drug conjugate (ADC) therapy for tumor-forming cancers. The purpose of this study is to learn about AGX101 effects and safety at various dose levels in an all-comers advanced solid cancer patient population.
- Conditions
- Cancer, Advanced Cancer, Locally Advanced Carcinoma, Metastatic Solid Tumor
- Trial name
- NCT06440005
- Testing
- AGX101
- Where
- 7 sites in United States
- Volunteers
- 80 people
- Sponsor
- Angiex, Inc.
Melanoma
A Study of AMNN107 in the Treatment of Metastatic and/or Inoperable Melanoma Harboring a c-Kit Mutation
The purpose of this study is to determine whether nilotinib is efficacious in the treatment of metastatic and/or inoperable melanoma harboring a c-Kit mutation.
- Trial name
- TEAM (NCT01028222)
- Testing
- Nilotinib, DTIC
- Where
- 49 sites in United States, Argentina and 12 more
- Volunteers
- 55 people
- Sponsor
- Novartis Pharmaceuticals
Pancreatic Cancer
TAS-102 (Lonsurf) in Metastatic or Locally Advanced Unresectable Pancreatic Adenocarcinoma Post First Line Chemotherapy (UF-STO-PANC-003)
This is an open-label, non-randomized, sequentially enrolling single arm phase II trial to evaluate the activity of TAS-102 in previously treated metastatic and locally advanced unresectable pancreatic cancer after progression…
- Trial name
- NCT02921737
- Testing
- TAS-102
- Where
- 3 sites in United States
- Volunteers
- 7 people
- Sponsor
- University of Florida
Colorectal Cancer (MSI-H)
Neoadjuvant Immunotherapy ± Radiotherapy in MSI-H/dMMR Locally Advanced Colorectal Cancer
This phase II clinical trial evaluates the efficacy and safety of three neoadjuvant regimens in patients with locally advanced microsatellite instability-high/mismatch repair-deficient (MSI-H/dMMR) colorectal cancer (CRC): 1)…
- Trial name
- TORCH-OPTIMA (NCT07403877)
- Testing
- Nivolumab, Ipilimumab (1mg/kg), PULSAR
- Where
- China
- Volunteers
- 114 people
- Sponsor
- Fudan University
Rectal Cancer, Adenocarcinoma, Neoadjuvant Chemoradiation
Multicenter, Prospective, RCT：Investigation of Combined Modality Therapy for Locally Advanced Mid/Low Rectal Cancer.
At present, the combined modality treatment of preoperative neoadjuvant chemoradiotherapy (NCRT) followed by radical surgery has become the standard of care for the locally advanced mid/low rectal cancer, having been proved to…
- Trial name
- NCT03042000
- Testing
- non-NCRT, NCRT, capecitabine with oxaliplatin
- Volunteers
- 1,200 people
- Sponsor
- Peking Union Medical College Hospital
Pulmonary Emphysema
Israeli 10 mL Bronchoscopic Lung Volume Reduction (BLVR) Phase 1/2 Emphysema Study - Initial Formulation
The purpose of this study is to evaluate the safety and efficacy of the Aeris BLVR System in patients with advanced emphysema.
- Trial name
- NCT00205907
- Testing
- BLVR Hydrogel
- Where
- Israel
- Volunteers
- 4 people
- Sponsor
- Aeris Therapeutics
Breast Cancer
A Real-world Efficacy and Safety Study of Amlotinib for HER2-negative Advanced Breast Cancer
This study analyses the efficacy and safety of amlotinib as a study drug in the treatment of HER-2 negative advanced breast cancer in the real world, including the number of treatment lines, monotherapy, combination therapy, and…
- Trial name
- NCT06340165
- Testing
- Anlotinib
- Where
- China
- Volunteers
- 153 people
- Sponsor
- The First Hospital of Jilin University
Epithelial Cancer
Randomized RT +/- Lapatinib for Advanced Solid Tumor Cancer Patients Receiving Radiation Therapy for Metastatic Disease
Lapatinib will prevent radiation-induced increase in Transforming Growth Factor alpha (TGFα), an important growth factor in cancer cell recovery after ionizing irradiation.
- Trial name
- NCT01427322
- Testing
- Lapatinib, Radiation therapy
- Where
- 2 sites in United States
- Volunteers
- 6 people
- Sponsor
- Virginia Commonwealth University
Crohns Disease
A Study to Evaluate the Effect of Fecal Transplant and Dietary Changes on Disease Activity in Patients With Crohn Disease on Advanced Therapies
Advanced therapies including biologics and small molecules target specific inflammatory pathways. IBD's multifactorial etiology means that blocking a single pathway may not be sufficient for all patients.
- Trial name
- BOOST-CD (NCT06890637)
- Testing
- Fecal Microbial Transplantation, Crohns Disease Exclusion Diet, Advanced therapy
- Where
- 6 sites in India
- Volunteers
- 168 people
- Sponsor
- All India Institute of Medical Sciences
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.